BEIJING, Feb. 5, 2025 /PRNewswire/ — In a record-breaking achievement for China’s film industry, as of 13:29 on February 5, 2025, the total box-office revenue of new films released during the 2025 Spring Festival holiday season exceeded 10 billion yuan (around $1.37 billion), according to movie data platform Beacon Pro.

The Spring Festival holiday season, which ran from January 28 to February 4, also saw the number of moviegoers break records: 187 million people attended theaters during the holiday.

The strong performance during the holiday season propelled China’s total film box office in 2025 to the top of the global list, exceeding that of North America.

During the holiday, the animated film “Ne Zha 2” stood out with a staggering box-office revenue of 4.839 billion yuan, and continues to shatter records in Chinese cinematic history, such as the viewership of animated films. Movie data platform Beacon Pro also predicts the movie’s final box-office takings may exceed 8.5 billion yuan, which is likely to top the all-time Chinese film box office chart and rewrite records.

Capitalizing on the domestic boom, the international trailer for “Ne Zha 2” was recently unveiled and is slated for release in Australia and North America in mid-February.

This Spring Festival also witnessed a slew of Chinese films achieving overseas success. “Detective Chinatown 1900,” “Creation of the Gods II: Demon Force,” and “The Legend of the Condor Heroes: The Gallants” garnered global attention and acclaim from international audiences.

“Creation of the Gods II: Demon Force” premiered simultaneously in 16 countries and regions outside of China, including the United States, France, the United Kingdom, and Bulgaria. In Australia and New Zealand, it reigned as the top-grossing movie for four consecutive days. In North America, the movie led the non-English language box office from January 31 to February 2.

“Detective Chinatown 1900” was released in multiple Spanish cities during the Spring Festival. It was screened in 213 cinemas in North America, and 93 cinemas in Australia and New Zealand, breaking the overseas screening record for Chinese-language films.

Many overseas viewers noted that Chinese films are leading in innovation in visual effects, storytelling, and cultural representation. Some particularly praised the quality of the English subtitles, which helped them better understand Chinese films and Chinese culture.

BANGKOK , Feb. 5, 2025 /PRNewswire/ — The Roads & Traffic Expo Thailand 2025, a leading event dedicated to road infrastructure, traffic management, and smart mobility solutions, will take place on 26-27 February 2025 at Hall EH 98, BITEC, Bangkok. The event is co-located with EVCharge Live Thailand 2025 and Solar & Storage Live, offering attendees access to three key industry exhibitions with a single pass, covering transportation, energy, and mobility solutions.

The event will bring together top global sponsors and exhibitors, including Greenwood Engineering and Star Systems International, who are at the forefront of innovation in road infrastructure and traffic technology. Attendees can explore cutting-edge solutions from exhibitors such as PSD Road Solution, Cleanozone, Tanattorn, Avery Dennison, Geveko Marking, and Teledyne, offering advanced technologies in road safety, traffic management, marking systems, and smart infrastructure solutions.

The conference will feature thought leaders and top decision-makers, including: Pornprom Vikitsreth, Chief Sustainability Officer and Advisor to the Governor of Bangkok, Bangkok Metropolitan Administration, as the Guest of Honor. Dr. Piyapong Jiwattanakulpaisarn, Inspector General, Ministry of Transport, addressing policy advancements for Thailand’s road and transport sector. Dr. Supakorn Siddhichai, Group Executive Vice President of the Digital Economy Promotion Agency (depa), provides insights on integrating digital technologies into modern road infrastructure. Tanita Sirisup, Acting Senior Executive Investment Advisor and Executive Director of the Foreign Investment Marketing Division, Board of Investment, discussing foreign investment opportunities in Thailand’s infrastructure sector. From strategies for safer roads to innovations in traffic management and smart mobility, the conference sessions will provide actionable insights for all attendees.

The event brings together transport authorities, city planners, EPCs, infrastructure developers, and technology providers, facilitating collaboration and business growth. Attendees will have the opportunity to participate in networking sessions, panel discussions, and product demonstrations, gaining insights into the future of road and traffic management in Thailand and beyond.

This event is free to attend. Registration is still open at www.terrapinn.com/MoreRoadsTrafTH25

The Roads and Traffic Expo Thailand 2025 will take place at Hall EH 98, BITEC, Bangkok, on 26-27 February 2025.

For more information on The Roads and Traffic Expo Thailand 2025, please visit: www.terrapinn.com/MoreRoadsTrafTH25

PR Newswire is the official news distribution partner of The Roads and Traffic Expo Thailand 2025.

EVCharge Live Thailand 2025

Conference dates and opening hours –
26 February 2025: 0900 – 1700
27 February 2025: 0855 – 1700

Exhibition dates and opening hours –
26 February 2025: 0830 – 1730
27 February 2025: 0830 – 1730

Venue: Hall EH98, BITEC, Bangkok, Thailand

About Terrapinn

Terrapinn has been sparking ideas, innovations and relationships that transform business for over 30 years. Using our global footprint, we bring innovators, disrupters and change agents together, discussing and demonstrating the technology, strategies and personalities that are changing the way the world does business. Whether you’re looking to make new connections, introduce product or inspire change in your industry, we invite you to join us as agitators of change. Terrapinn – spark something

Terrapinn – spark something.
www.terrapinn.com

Initiatives are maturing from pilots and proofs of concept to targeted, enterprise-wide strategies

ARMONK, N.Y., Feb. 5, 2025 /PRNewswire/ — IBM (NYSE: IBM) today released its annual expectations for technology and transformation in the global financial services industry in the year ahead in the IBM Institute for Business Value 2025 Outlook for Banking and Financial Markets.

2025 Global Outlook for Banking and Financial Markets

Key Insights

• Gen AI adoption is set to soar. Only 8% of banks were developing generative AI systematically in 2024, and 78% had a tactical approach. As banks move from pilots to execution, more are redefining their strategic approach to service expansion, including agentic AI. 
• Steady banking convergence is giving way to contrasting financial performance. Re-imagining the business model/processes and, importantly, execution will separate the winners from the rest.
• 60% of banking CEOs surveyed acknowledge they must accept some level of risk to harness automation advantages and enhance competitiveness.¹
• While over 16% of clients worldwide are comfortable with a branchless, fully digital bank as their primary banking relationship, competition is shifting from mass market digital offers to higher-value services, including embedded finance and advisory services to affluent investors and small and medium-size enterprises (SMEs).

“We are seeing a significant shift in how generative AI is being deployed across the banking industry as institutions shift from broad experimentation to a strategic enterprise approach that prioritizes targeted applications of this powerful technology,” said Shanker Ramamurthy, IBM Consulting’s Global Managing Director Banking & Financial Markets. “As banks and other financial institutions around the world gear up for a pivotal year of investing in transformation, technology, and talent, we anticipate their efforts coalescing around initiatives using generative AI to level up customer experience, boost operational efficiency, reduce risks and modernize IT infrastructure.”

The report shares insights from analysis of industry C-suite leader sentiment, bank customer behavior and economic data from eight major markets—the United States, Canada, European Union, United Kingdom, Japan, China, India, and Japan–and what financial institutions and their ecosystem partners can glean from the trends.

For additional perspective and to download the full report, visit https://ibm.co/2025-banking-financial-markets-outlook.

IBM is a leading provider of enterprise AI, hybrid cloud architecture, security and ESG insights to the global financial services sector. Its deep industry expertise, extensive portfolio of services and solutions, and its robust ecosystem of fintech partners, empower collaboration, innovation, and creation with clients. As a trusted partner to banks, insurers, capital markets and payments providers, IBM guides financial institutions on all stages of their digital transformation journeys through IBM Consulting and delivers the proven infrastructure, software, and services they need through IBM Technology. For more information, visit www.ibm.com/industries/banking-financial-markets.

The IBM Institute for Business Value, IBM’s thought leadership think tank, combines global research and performance data with expertise from industry thinkers and leading academics to deliver insights that make business leaders smarter. For more world-class thought leadership, visit www.ibm.com/ibv.

About IBM
IBM is a leading provider of global hybrid cloud and AI, and consulting expertise. We help clients in more than 175 countries capitalize on insights from their data, streamline business processes, reduce costs and gain the competitive edge in their industries. Thousands of government and corporate entities in critical infrastructure areas such as financial services, telecommunications and healthcare rely on IBM’s hybrid cloud platform and Red Hat OpenShift to affect their digital transformations quickly, efficiently and securely. IBM’s breakthrough innovations in AI, quantum computing, industry-specific cloud solutions and consulting deliver open and flexible options to our clients. All of this is backed by IBM’s long-standing commitment to trust, transparency, responsibility, inclusivity and service. Visit www.ibm.com for more information.

Media Contact

Mary Ellen Higgins
IBM Global Financial Services Industry External Communications
maryellen.higgins@ibm.com
781.789.1911

IBM Corporation logo.

SINGAPORE, Feb. 5, 2025 /PRNewswire/ — At FY Ads Singapore, we specialize in driving meaningful growth through tailored Xiaohongshu marketing and digital strategies designed to reach key markets. Recently, we had the privilege of helping PS Café, one of Singapore’s most iconic dining destinations, enhance their presence on two of China’s leading platforms – Xiaohongshu (小红书, known as Red Note) and Meituan Dianping (美团点评). Here’s a closer look at how our expert Xiaohongshu marketing and Meituan Dianping strategies helped PS Café amplify their brand, attract more customers, and strengthen their connection with Chinese tourists.

Crafting a Customized Marketing Strategy for PS Café

When PS Café approached us, they understood the importance of engaging the growing Chinese consumer base, especially on platforms like Xiaohongshu and Meituan Dianping, where users actively seek lifestyle and dining recommendations. With a reputation for high-quality food and a welcoming atmosphere, PS Café was eager to expand its reach to Chinese tourists. Our role was clear: leverage Xiaohongshu marketing and Meituan Dianping marketing to communicate PS Café’s unique offerings to the Chinese market.

Key Strategies for Xiaohongshu Marketing

Xiaohongshu (Little Red Book) is a powerful platform for food, lifestyle, and travel-related content, particularly among younger, affluent Chinese consumers. Here’s how we leveraged Xiaohongshu marketing for PS Café:

• Content Creation & Curation: We crafted visually appealing posts that highlighted PS Café’s signature dishes, charming ambiance, and premium offerings. Each post was tailored to resonate with Xiaohongshu‘s sophisticated audience, emphasizing PS Café’s aesthetic appeal and upscale dining experience.
• Influencer Collaborations: Collaborating with influential Key Opinion Leaders (KOLs) in the food and lifestyle space, we amplified PS Café’s presence. These partnerships generated authentic, relatable content that sparked excitement and curiosity among Chinese users.
• User-Generated Content Campaigns: Encouraging customers to share their PS Café experiences on Xiaohongshu helped create organic engagement, expanding the café’s reach through peer-to-peer recommendations.
• Hashtag Strategy & Local Engagement: We utilized targeted hashtags and location-based tagging to ensure PS Café’s posts reached the right audience, particularly Chinese tourists planning their Singapore visit. This approach reinforced the café’s relevance and appeal within the Xiaohongshu community.

Maximizing PS Café’s Visibility on Meituan Dianping

Meituan Dianping is one of China’s largest platforms for local services, including dining. We recognized the immense potential for PS Café to engage Chinese tourists and locals alike. Here’s how we boosted their presence:

• Restaurant Listings & Reviews: We optimized PS Café’s profile on Meituan Dianping, highlighting key selling points such as the café’s ambiance, high-quality offerings, and customer service. Positive reviews from satisfied customers further enhanced the café’s credibility and visibility.
• Localized Promotions & Offers: We developed exclusive discounts and promotions for Meituan Dianping users, encouraging both first-time visitors and returning customers to visit PS Café.
• Geo-targeted Ads: Leveraging Meituan Dianping’s geo-targeting capabilities, we ensured PS Café’s promotions reached Chinese tourists already in Singapore. This increased the likelihood of conversions, driving foot traffic from online engagement to in-store visits.

The Results: A Stronger Connection with Chinese Consumers

Thanks to our targeted Xiaohongshu marketing and Meituan Dianping marketing strategies, PS Café has successfully strengthened its digital presence in China. Here’s what we accomplished:

• Increased Engagement on Xiaohongshu: PS Café’s posts gained traction, with users regularly sharing their experiences, fostering a growing community of loyal fans.
• Enhanced Visibility on Meituan Dianping: The optimized restaurant listing and engaging reviews attracted Chinese tourists who discovered PS Café through Meituan Dianping, leading to greater brand awareness and foot traffic.
• Boosted Foot Traffic to PS Café: By engaging both online and offline channels, we increased the number of Chinese customers dining at PS Café, particularly during peak tourism seasons.

Why FY Ads is Your Ideal Partner for Xiaohongshu Marketing in Singapore

At FY Ads, we understand the intricacies of Xiaohongshu marketing and the broader Chinese digital landscape. Our expertise in leveraging Xiaohongshu and Meituan Dianping marketing allows us to connect brands with Chinese consumers in impactful ways. Whether you’re in the F&B industry, tourism, or another sector, we have the tools, strategies, and knowledge to elevate your brand’s presence in China.

Ready to grow your brand through Xiaohongshu marketing and Meituan Dianping marketing? Let’s work together to create a tailored strategy that captures the attention of Chinese consumers and drives meaningful results.

Contact us today at www.fy-ads.com.

SHANGHAI, Feb. 5, 2025 /PRNewswire/ — In the field of biopharmaceuticals, every technological innovation has the potential to revolutionize treatment strategies. Sanyou Bio’s Intelligent Hundred-Trillion Molecule Library (AI-STAL) has emerged from scratch as a shining star, forged through a decade of relentless effort — growing from weakness to strength — gradually building a vast and advanced technological system that paves a new path for drug discovery. The AI-STAL platform not only witnessed the rapid development of biotechnology, but also foreshadowed a new direction for future biopharmaceutical research.

2015: The Emergence of AI-STAL

The year 2015 marked the inception of Sanyou Bio’s technological journey, laying the foundation for its core technology platform. The R&D team devoted itself to the development of display vectors, ultimately establishing a proprietary system with independent intellectual property rights. This process was far from smooth — our scientists delved deeply into phage display technology, rigorously screened, modified, and optimized various plasmid vectors. Through countless experiments and refinements, they successfully constructed a unique phage display plasmid vector with an unparalleled sequence. This achievement not only ensured Sanyou Bio’s autonomy and independence at the technical level, but also laid a crucial foundation for subsequent breakthroughs. At the same time, Sanyou Bio demonstrated remarkable foresight in conceptual design of molecule libraries, proposing the designs for multi-pathway antigen libraries and diverse molecule libraries. At that time, the conventional approaches to antigen and molecule library construction were relatively simple and limited. Through the integration and innovation of multidisciplinary knowledge from immunology, molecular biology, and other disciplines, our research team envisioned a strategy to obtain antigens from multiple sources and built diverse molecule libraries, catering to the growing and varied needs of drug R&D.

2016: The Beginning of Commercialization

In 2016, Sanyou Bio took a significant step towards commercialization. The team successfully integrated hybridoma technology with phage display technology, creating a powerful synergy. Hybridoma technology is known for producing highly specific monoclonal antibodies but suffers from issues such as low screening efficiency. In contrast, phage display technology offers high-throughput screening capabilities. By combining the strengths of both methods, Sanyou Bio’s researchers developed an innovative approach: first generating preliminary specific antibodies using hybridoma technology, and then further screening and optimizing these antibodies through phage display technology, significantly improving the quality and screening efficiency of the antibodies. Based on this technology, the team also advanced the conceptual design of synthetic and semi-synthetic antibody libraries. By employing artificial synthetic and semi-synthetic approaches, the team innovatively constructed antibody libraries with increased diversity and specificity, further strengthening the company’s technological portfolio. In terms of commercial applications, Sanyou Bio became a pioneer in the commercial application of mouse immune libraries in China. We brought our independently developed mouse immune library to the market, providing efficient antibody screening tools for many research institutions and pharmaceutical companies. This breakthrough quickly earned Sanyou Bio a good reputation and growing influence within the industry.

2017: The Strengthening of the Technological Foundation

In 2017, Sanyou Bio focused on sharpening its technological foundation. In the conceptual design of the 100-billion-level fully human antibody library, the team conducted in-depth research on the structure and functional characteristics of fully human antibodies, integrating advanced gene synthesis and cloning technologies to envision the construction of a vast fully human antibody library at the sub-trillion level. Through extensive preliminary studies and experimental simulations, the construction strategy and technical route for the library were determined. Simultaneously, the conceptual design of the common light chain library was also carried out. Our researchers discovered that the stability and compatibility of the light chain play a crucial role in antibody performance. This led to the proposal of building a common light chain library, providing a more stable and efficient source of light chains for subsequent antibody development. Additionally, Sanyou Bio further upgraded the mouse immune antibody library. By optimizing immunization strategies and screening workflows, the affinity and specificity of antibodies within the library have been improved, significantly increasing its application value in drug R&D.

2018: The Launch of AI-STAL 1.0

2018 was a milestone year for Sanyou Bio, marking major breakthroughs in the development of the first-generation molecule library. The team successfully constructed a 100-billion-level fully human antibody library, setting a new record in the industry. The construction process faced numerous challenges, including the complexity and difficulty of gene synthesis and the low efficiency of library assembly. By optimizing gene synthesis methods and adopting high-efficiency cloning technology and screening strategies, our researchers overcame many obstacles, ultimately creating a fully human antibody library with a molecule scale several times larger than previous billion-level libraries. With the significant increase in library capacity, the number of preferred lead molecules also increased dramatically, providing a broader selection of high-quality candidate molecules for drug R&D. In the same year, Sanyou Bio also successfully built and set a record for a 10-billion-level naïve single-domain antibody library. At the time, the capacity of largest available single-domain antibody library worldwide contained only more than 4 billion. Leveraging its advanced technology platform and innovative construction strategies, Sanyou Bio broke this limitation. The team extracted single-domain antibody genes from animals such as alpacas and optimized gene cloning and expression conditions to construct a naïve single-domain library at the 10-billion level eventually. By the end of the year, Sanyou Bio had also completed the construction of a billion-level common light chain library. Throughout this process, our researchers meticulously screened and assembled light chain genes to ensure the quality and stability of the common light chain library, laying a solid foundation for the subsequent development of a trillion-level common light chain antibody library.

2019: The Development of Single-domain Antibody Library

In 2019, Sanyou Bio made significant progress in the development of single-domain antibody libraries. The conceptual design of a trillion-level fully human antibody library advanced steadily. Through data analysis and technical summary of the previously constructed 100-billion-level fully human antibody library, the team proposed the idea of building a trillion-level fully human antibody library. The plan focused on further optimizing gene synthesis and library construction technologies to increase the diversity and complexity of antibodies. At the same time, Sanyou Bio successfully constructed a super 100-billion-level single-domain antibody library, once again setting a new record in the industry. To achieve this, our research team introduced innovative synthesis technologies and screening methods to improve both the quality and screening efficiency of the single-domain antibody library. In addition, the validation of the billion-level common light chain library was completed. Through a series of rigorous experimental verifications, the stability and effectiveness of the library in antibody construction were approved, providing a reliable source of light chains for antibody development in future.

2020: Deep Technological Advancements

In 2020, Sanyou Bio underwent a deep technological upgrade. In the conceptual design of humanized semi-synthetic antibodies, based on their in-depth understanding of the human immune system and antibody structure, the team proposed to construct a humanized semi-synthetic antibody library through a novel combination of artificial synthesis and genetic modification. They envisioned improving the degree of humanization and reducing immunogenicity while retaining the natural activity of antibodies. Simultaneously, the conceptual design of humanized single-domain antibody library was also carried out. In view of the unique properties of single-domain antibodies, our researchers focused on humanizing the single-domain antibody framework to enhance the safety and effectiveness of the molecules for use in human body, thus constructing the humanized single-domain antibody library. Additionally, the conceptual design of the common light chain library concept was been further refined. The team conducted in-depth molecular-level research on the structure and function of common light chain, providing critical theoretical support for constructing a more efficient and optimized common light chain antibody library.

2021: Establishment of 3 Trillion-level Antibody Libraries

2021 was another milestone year for Sanyou Bio, with the successful completion of three trillion-level antibody libraries. By setting another new record in the industry, the establishment of the trillion-level fully human recombinant antibody library was a groundbreaking achievement. During the construction process, the team employed advanced gene recombination technologies and highly efficient library screening methods, ensuring exceptional antibody diversity and quality in the library. Building upon this success, the construction of the trillion-level fully human semi-synthetic antibody library was also completed. This library represented an upgraded achievement through gene recombination between CDRs based on the trillion-level fully human antibody library. Using precise gene editing techniques, our researchers optimized CDR sequences, enhancing antibody specificity and affinity. Another major breakthrough, the trillion-level humanized single-domain antibody library was also successfully established in record time. This library was built upon a highly humanized single-domain antibody framework and constructed through precise directly synthesis with reference to the characteristics of CDR sequences in nature. In same year, the screening and validation of the first trillion-level molecule library achieved outstanding results. For a single target protein, the average number of lead molecules was as high as hundreds, and the diversity was extremely high, providing abundant high-quality candidate molecules for drug R&D.

2022: The Launch of Super-trillion-level Platform

In 2022, Sanyou Bio achieved new milestones in development of molecule library and platform integration. The trillion-level fully human common light chain antibi library was successfully constructed and set a record in the industry. This library effectively addressed the challenge of light and heavy chain mismatching in the construction of “Two-in-One” bispecific antibodies, providing strong support for the development of bispecific antibodies, dual-target or dual-epitope ADCs, and other antibodies. With this addition, the total capacity of Sanyou Bio’s four trillion-level antibody libraries reached an unprecedented 7 trillion. On June 3, 2022, Sanyou Bio integrated the super-trillion-level molecule library and related cutting-edge technologies into a unified, comprehensive platform, named it “Sanyou Super-Trillion Innovative Antibody Drug Discovery Platform (STAL)”, and officially released it to the public. STAL was designed to integrate a variety of advanced techniques and rich molecule library resources, providing a one-stop solutions for drug R&D. Meanwhile, the construction and verification of the 100-billion-level cyclic peptide molecule library was also successfully completed. By utilizing innovative peptide synthesis techniques and advanced screening methods, our researchers developed a cyclic peptide molecule library with unique structural and functional properties, opening new frontiers for cyclic peptide drug R&D.

2023: A Giant Leap in Library Capacity

In 2023, Sanyou Bio achieved a giant leap in the capacity of its super-trillion molecule library. The trillion-level peptide library was successfully constructed and set a record in the industry. The team made new breakthroughs in peptide synthesis technology and library construction methods, bringing the total capacity of the peptide library to 3 trillion. As a result, the cumulative library capacity of super-trillion molecule library exceeded 10 trillion. In October 2023, Sanyou Bio conducted a comprehensive review and official release of its Super-Trillion Innovative Biologics Discovery Platform, further refining the functions and service system. By the end of 2023, Sanyou Bio completed the construction and validation of the 100-billion-level Anti-Calin molecule library. Anti-Calin molecules possess unique structural and functional properties, offering broad application prospects in the field of targeted therapy. The successful development of such library provided a critical molecule resource for the development of related drugs.

2024: AI-driven Design

In 2024, Sanyou Bio introduced AI technology to assist in the design of molecule library. The proof of concept of the second-generation super-trillion single-domain antibody library was launched first. The team used AI algorithms to analyze and predict the structure and function of single-domain antibodies and optimize the library’s construction strategy. Through extensive simulation experiments and data analysis, the construction direction and key technical parameters of the second-generation super-trillion single-domain library were determined. In October 2024, the construction and verification of the second-generation super-trillion single-domain concept library was completed. At present, such second-generation single-domain library is being constructed in full swing. Simultaneously, the construction of the second-generation super-trillion peptide library is also being actively promoted. With the assistance of AI technology, the team optimized the sequence and structure of peptides to improve the quality and screening efficiency of the peptide library. In addition, the conceptual design of nucleic acid molecule library was also put on the agenda. Our researchers envisioned leveraging AI-driven design to construct nucleic acid molecule library with specific functions, paving new technical pathways for fields such as gene therapy.

2025: The Launch of AI-STAL 2.0

In January 2025, AI-STAL 2.0 was officially launched, initiating a multi-year plan to complete the construction and gradual deployment of the Intelligent 100-trillion Molecule Library. It is planned to launch 10-trillion novel single-domain library, fully integrate AI technology, optimize the gene sequence of single-domain antibodies through AI algorithms, and improve the diversity and specificity of antibodies in new molecule library. Meanwhile, AI will be integrated into the entire process of antibody discovery and optimization. From the design of antibody genes, the construction of libraries, to the screening and optimization of antibodies, AI is used throughout. Using AI algorithms in analysis and data-mining of large amount of biological data could quickly and accurately discovery potential antibody molecules, and then optimize them, greatly improving the efficiency and success rate of antibody R&D.

Future Outlook

Looking to the future, AI-STAL 2.0 will develop in a broader application. In terms of development direction, it explores towards 5 major directions, including indications, molecular formats, application scenarios, mini-programs, and important targets. In terms of molecular types, it covers 6 types of molecules, including fully human monoclonal antibodies, common light chain antibodies, humanized single-domain antibodies, cyclic peptide molecules, ADC molecules, and mRNA molecules, proving diversified molecular tools for the treatment of different diseases. In terms of application scenarios, it is adapted to 8 key scenarios, including ELISA, WB, IHC, IF, IP-ID, FC, SPA, and SPB. In terms of technology integration, 7 AI-driven programs are integrated, including de novo generation, epitope prediction, immunogenicity prediction, druggability prediction, specificity prediction, affinity predication, and one-click molecule design, to improve the intelligence level of R&D. In terms of disease research, it focuses on 9 major human diseases, including tumors, autoimmune, infection, metabolism, ophthalmology, neurology, cardiovascular, anti-aging, and various rare diseases. In terms of target exploration, it concentrates on in-depth research over 100K important targets to lay a solid foundation for the development of more innovative drugs.

Sanyou Bio’s Intelligent 100-Trillion Molecule Library (AI-STAL) has evolved from its inception in 2015 into a powerful technology platform in the field of biologics after 10 years of relentless effort and technological innovation. Moving forward, with the deep integration of AI technology and continuous expansion, AI-STAL will play an even more crucial role in tackling major human diseases, developing innovative drugs, and making outstanding contributions to human health globally.

About Sanyou Bio

Sanyou Biopharmaceuticals Co., Ltd. is a high-tech biopharmaceutical company with the vision of “improving the quality of human life through innovative biologics” and the mission of ” to make the R&D easy for innovative biologics”. The company is headquartered in Shanghai, China, with subsidiaries in the United States, Europe, and other regions. It has over 20,000 square meters of R&D and GMP facilities that are currently in operation or under planning.

The company has established a world-leading preclinical intelligent and integrated R&D platform for innovative biologics, centered around an innovative platform of super-trillion antibody library. This platform accelerates the development of innovative biologics across four dimensions: new drug discovery, preclinical research, AI-assisted drug development, and frontier scientific research.

Sanyou provides a comprehensive “4C” business model for innovative biologics, combining differentiated CRO, integrated CDO, collaborative CPO, and specialized CRS. The company has built a global marketing network and established business with over 1,200 pharmaceutical and biotech companies worldwide. It has completed more than 1,200 new drug discovery and development service projects, with over 50 collaborative R&D projects, including 9 that have obtained IND approval. The company has also developed thousands of RUO reagents. Sanyou has also received a number of nationwide and Shanghai recognitions and awards.

BEIJING, Feb. 5, 2025 /PRNewswire/ — China’s leading baijiu maker Wuliangye sent its Spring Festival greetings to the world through a 3D advertisement released on January 27 at the Times Square, New York.

In the joyful and peaceful Spring Festival, Chinese civilization concepts such as peace and harmony are spread to enhance mutual understanding, respect, and interaction among peoples. 

The advertisement presented the Wuliangye brand through a lovable animated giant panda, who unfolded a couplet meaning “harmony”. It marked the integration of Wuliangye’s brand culture of “harmony” with the Spring Festival, conveying the good wishes of the Chinese nation to the world for a new future highlighting global “harmony”.

To observe the festival, Chinese people always prepare sumptuous food and make toasts to their families, friends and ancestors with Chinese baijiu. As one of the oldest Chinese baijiu, Wuliangye reflects the connections and pursuits of the Chinese people, becoming a cultural symbol in the Spring Festival celebrations.

To welcome the Year of the Snake, the first edition after the UNESCO added the Spring Festival, the social practices of the Chinese people in celebration of the traditional new year to its Representative List of the Intangible Cultural Heritage of Humanity, Wuliangye launched the Times Square 3D advertisement, not only conveying blessings but also exhibiting the charm of Chinese baijiu culture.

Wuliangye baijiu, made from sorghum, rice, sticky rice, wheat and corn, is the world’s first distilled liquor made from five types of grains. Wuliangye has ancient fermentation pits, which are precious tangible cultural heritage and have been fermenting for 700-odd years since the Yuan and Ming dynasties. Rich microorganisms in the pits mud endow Wuliangye with unparalleled unique flavor and delicate taste. Also, the brewing techniques that have been passed down for over a thousand year have finally created the unique flavor and quality of Wuliangye.

In recent years, Wuliangye has been actively going global. It has set foot in multiple countries and regions across the five continents through a “Harmony Global Tour” campaign. To expand international business, the Chinese baijiu maker has established three international marketing hubs in the Asia Pacific, Europe, and the Americas, and made its products available in duty-free stores, retail outlets, catering services, e-commerce platforms, and special channels.

Original link: https://en.imsilkroad.com/p/344240.html